Phase 2 N=13 Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Response Rate — 1; 2; 4 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=306 An Evaluation of Weekly Tafenoquine
Falciparum Parasitaemia
Primary: Prophylactic Outcome Defined by the Subject Having no Positive Smears — 93; 90; 92; 6 participants
Phase 2 N=158 Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
Leukemia
Primary: Overall Survival (OS) — 45.9 Percentage of participants
Phase 2 N=60 Caffeine/Propranolol Intervention for Acute Migraine
Migraine Disorders
Primary: Percentage of Participants Reporting Pain Relief at 2 Hrs Post First Administration of Caffeine/Propranolol (Defined as a Decrease in Headache Pain Intensity From Severe…
Phase 2 N=26 Prolonged Exposure for Post Traumatic Stress Disorder (PTSD) With/Without Yohimbine
Post-Traumatic Stress Disorder
Primary: Trauma-Cued Heart Rate Reactivity — 71.01; 75.08 beats per minute — p=<0.001
Phase 2 N=12 Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence
Major Depressive Disorder · Depression, Unipolar · Recurrence
Primary: Change in HAM-D-17 Total Score — -5.8; -9.5 units on a scale
Phase 2 N=20 D2212C00002 J-Phase II Study
Idiopathic Pulmonary Fibrosis
Primary: Safety and Tolerability Primarily Assessed by the Number of Patients With Adverse Events — 8; 7; 2; 1 Patients
Phase 2 N=70 Transcranial Magnetic Stimulation for Tinnitus
Tinnitus
Primary: Change in Tinnitus Functional Index (TFI) Score — -13.8; -2.9 units on TFI scale; change from baseline
Phase 2 N=32 Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
Breast Cancer
Primary: 5-Year Relapse-free Survival Rate — 53 percentage of participants
Phase 2 N=41 Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis
Primary: Mean Percent Change in Papilloma Growth Rate at 12 Month Measurement Compared to Baseline — -5.4; -15.2 percent change in mean growth rate — p=0.57
Phase 2 N=9 An Open-label Extension Study of PSMA ADC 2301 in mCRPC
Prostate Cancer
Primary: Percentage of Participants With Total Serum PSA Response — 67; 33; 33; 0 % of responders
Phase 2 N=46 Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer
Breast Cancer
Primary: Proportion of Confirmed Tumor Responses (Complete or Partial Response) — 0.08; 0.05 proportion
Phase 2 N=119 A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Prostate Cancer
Primary: Percentage of Participants With Total Serum PSA Response — 29; 32; 11; 21 % of responders
Phase 2 N=54 Topical Anesthetic Use In Pessary Management
Pain
Primary: VAS Score at the Time of Pessary Removal Adjusting for Baseline Pain — 1.76; 3.81 Centimeters — p=.02
Phase 2 N=194 Study to Evaluate the Safety and Efficacy of CAT-354
Asthma
Primary: Change From Baseline in the Mean Asthma Control Questionnaire (ACQ) Score at Day 92 — 2.63; 2.72; 2.62; 2.72 units on a scale — p=0.573